Audit Committee & Capital Markets BOD

Aphios Corporation is seeking an experienced independent Board Director with strong Audit Committee, public-company and capital-markets experience to help guide the Company through its next stage of growth, institutional financing and public-market readiness.

Aphios is a clinical-stage biotechnology company advancing a diversified portfolio of therapeutics and proprietary drug-delivery technologies. The Company is strengthening its Board and governance infrastructure as it prepares for institutional financing and the public markets.

We are seeking a Director with significant experience in several of the following areas:

• Audit Committee leadership or membership
• SEC financial reporting and public-company governance
• Financial oversight, internal controls and risk management
• Nasdaq or other U.S. public-market requirements
• IPO, direct listing or other public-company transactions
• Institutional financing and capital markets
• Investment banking, institutional investing or investor relations
• Life sciences or biotechnology financing and corporate development

The ideal candidate may be a current or former:

• Public-company CFO, CAO or senior financial executive
• Audit Committee Chair or financially sophisticated public-company director
• Senior investment banker or capital-markets executive
• Institutional healthcare or life-sciences investor
• Biotechnology or healthcare executive with significant public-company experience

Experience with
SEC reporting, Audit Committee responsibilities, internal controls and public-company governance is highly desirable.

Experience with biotechnology, pharmaceuticals, healthcare or other innovation-driven companies is preferred.

Aphios is expanding and strengthening its Board as the Company advances:

• Institutional and strategic capital formation
• SEC and Nasdaq readiness
• Audit Committee and governance infrastructure
• Financial reporting and internal-control disciplines
• Strategic partnering and corporate development
• Engagement with institutional investors and the public markets

The new Director is expected to qualify as an independent director and ideally bring the financial sophistication appropriate for service on the Company’s Audit Committee.

The Director will have the opportunity to:

• Help shape Aphios’ Audit Committee and public-company governance infrastructure
• Provide Board-level oversight of financial reporting, audit and internal controls
• Advise management on SEC and Nasdaq readiness
• Strengthen Aphios’ credibility with institutional investors and capital-market participants
• Contribute capital-markets perspective to financing and strategic decisions
• Help guide a clinical-stage biotechnology company through an important corporate transition

• Equity-based Board compensation
• Designed to align the Director with long-term shareholder value creation